Literature DB >> 18488857

[Infections in diabetic patients--a two-year experience from the Diabetic Foot Unit at Wolfson Medical Center].

Ludmilla Lysyy1, Shmuel Ovadia, Tatiana Zudkov, Israel Koper, Gisele Zandman-Goddard.   

Abstract

Diabetes mellitus is the main cause for limb amputations in the western world. Leg ulcers among patients with diabetes mellitus is the leading cause in up to 85% of cases of nontraumatic amputations of the lower limbs in this patient population. Bacterial infections penetrate the leg ulcers causing further complications in the diabetic patient. The rationale of establishing the Diabetic Foot Unit in these patients is to strive to maintain an intact limb. Some studies indicate that there can be a substantial reduction in leg amputations in diabetics who are treated by a multidisciplinary medical team. In late 2002, the Diabetic Foot Unit was established at the Wolfson Medical Center teamed by a medical and nursing staff specializing in the treatment of the diabetic foot. The aim of this study was to identify the microbial agents leading to leg ulcers, and to follow the definitive therapy and outcome for these diabetic patients. The data was retrieved from medical files over a 2 year period (2003-2004). The patients received conservative as well as surgical treatment. The major microbial agents were Gram-negative species, and some patients harbored resistant bacteria such as ESBL and MRSA. Less than 11% of patients required major limb amputation. The percent of major amputations in our specialized unit was comparable to other such units around the world.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18488857

Source DB:  PubMed          Journal:  Harefuah        ISSN: 0017-7768


  1 in total

1.  Chronic neuropathic ulcer is not the most common antecedent of lower limb infection or amputation among diabetics admitted to a regional hospital in Jamaica: results from a prospective cohort study.

Authors:  Jeffrey M East; Delroy A Fray; Dwayne E Hall; Chapman A Longmore
Journal:  BMC Surg       Date:  2015-09-21       Impact factor: 2.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.